/
KIN
$9.25prev close
No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
P/S (TTM)
52.8
Kindred Biosciences, Inc.
Kindred Biosciences, Inc. is a biopharmaceutical firm dedicated to the advancement of biological therapies specifically for companion animals. The company maintains an extensive pipeline of innovative biologics, spanning diverse therapeutic categories, underpinned by a robust intellectual property portfolio. Key development programs include treatments for canine atopic dermatitis, utilizing both interleukin-31 and interleukin-4R, as well as KIND-030 to combat parvovirus in dogs. Additionally, KIND-510a targets non-regenerative anemia in cats, while an anti-TNF antibody is being developed for canine inflammatory bowel disease. Further candidates within its biologics portfolio are also under investigation. Established in 2012, Kindred Biosciences is headquartered in Burlingame, California.
comingsoon.markmonitor.com- Employees
- 63
- IPO / List date
- Dec 12, 2013
- HQ
- US
Held by traders on TradeandTell
No one on the platform currently holds KIN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KIN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KIN yet.
